Swedbank AB Sells 35,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Swedbank AB cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 283,362 shares of the biopharmaceutical company’s stock after selling 35,000 shares during the period. Swedbank AB owned approximately 0.22% of Halozyme Therapeutics worth $13,548,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of Halozyme Therapeutics by 5.0% in the 2nd quarter. AQR Capital Management LLC now owns 47,773 shares of the biopharmaceutical company’s stock valued at $2,501,000 after acquiring an additional 2,265 shares during the last quarter. Mackenzie Financial Corp increased its stake in Halozyme Therapeutics by 42.3% in the second quarter. Mackenzie Financial Corp now owns 14,779 shares of the biopharmaceutical company’s stock valued at $774,000 after purchasing an additional 4,393 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Halozyme Therapeutics in the second quarter worth $209,000. Algert Global LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $670,000. Finally, Creative Planning grew its holdings in shares of Halozyme Therapeutics by 43.2% in the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after buying an additional 11,249 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.4 %

HALO stock opened at $56.64 on Friday. The company has a market cap of $7.21 billion, a price-to-earnings ratio of 18.76, a P/E/G ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The business has a 50 day moving average price of $50.65 and a two-hundred day moving average price of $54.33. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Analysts Set New Price Targets

HALO has been the topic of several recent analyst reports. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, HC Wainwright upped their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.